Pfizer reviews mixed gross sales of $15 billion for Covid vaccine and antiviral therapy in first quarter


Albert Bourla, chief govt officer of Pfizer pharmaceutical firm, arrives to ring the closing bell on the New York Inventory Trade.

Drew Angerer | Getty Photographs

Pfizer beat on its prime and backside line in its first quarter earnings report, pushed by sturdy gross sales of its Covid vaccine and oral antiviral therapy.

The pharmaceutical big stated it bought $13.2 billion of its Covid vaccine and $1.5 billion of its antiviral therapy Paxlovid within the first quarter.

Here is how Pfizer carried out in comparison with what Wall Avenue anticipated, primarily based on analysts’ common estimates compiled by Refinitiv:

  • Adjusted EPS: $1.62 per share, vs. $1.47 anticipated
  • Income: $25.66 billion, vs. $23.86 billion anticipated

Shares of Pfizer had been successfully flat in premarket buying and selling.

The corporate reaffirmed its full-year 2022 steerage of $32 billion in Covid vaccine gross sales and $22 billion for Paxlovid.

CNBC Well being & Science

Learn CNBC’s newest international protection of the Covid pandemic:

This can be a creating story. Please examine again for updates.

Leave a Reply

Your email address will not be published.